Impact of allopurinol use on urate concentration and cardiovascular outcome
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of ≤6 mg dl−1. • High‐dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients. WHAT THIS STU...
Uloženo v:
| Vydáno v: | British journal of clinical pharmacology Ročník 71; číslo 4; s. 600 - 607 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford, UK
Blackwell Publishing Ltd
01.04.2011
Blackwell Blackwell Science Inc |
| Témata: | |
| ISSN: | 0306-5251, 1365-2125, 1365-2125 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of ≤6 mg dl−1.
• High‐dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients.
WHAT THIS STUDY ADDS
• Less than 50% of patients taking allopurinol reached target urate concentration.
• Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality in all patients on allopurinol treatment.
AIMS To characterize patients with urate measurements by urate‐lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes.
METHODS A cohort study using a record‐linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined.
RESULTS Six thousand and forty‐two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl−1. Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non‐ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95–1.26] and the non‐ULT group with urate >6 mg dl−1 (adjusted HR 1.07, 95% CI 0.89–1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9–86.1) per 1000 person years for the 100 mg group, 69.7 (49.6–89.8) for the 200 mg group and 47.6 (38.4–56.9) for the ≥300 mg group. Compared with low‐dose (100 mg) users, high‐dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50–0.94) and mortality (adjusted HR 0.75, 95% CI 0.59–0.94).
CONCLUSIONS Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality. |
|---|---|
| AbstractList | To characterize patients with urate measurements by urate-lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes.AIMSTo characterize patients with urate measurements by urate-lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes.A cohort study using a record-linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined.METHODSA cohort study using a record-linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined.Six thousand and forty-two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl(-1) . Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non-ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95-1.26] and the non-ULT group with urate >6 mg dl(-1) (adjusted HR 1.07, 95% CI 0.89-1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9-86.1) per 1000 person years for the 100 mg group, 69.7 (49.6-89.8) for the 200 mg group and 47.6 (38.4-56.9) for the ≥300 mg group. Compared with low-dose (100 mg) users, high-dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50-0.94) and mortality (adjusted HR 0.75, 95% CI 0.59-0.94).RESULTSSix thousand and forty-two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl(-1) . Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non-ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95-1.26] and the non-ULT group with urate >6 mg dl(-1) (adjusted HR 1.07, 95% CI 0.89-1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9-86.1) per 1000 person years for the 100 mg group, 69.7 (49.6-89.8) for the 200 mg group and 47.6 (38.4-56.9) for the ≥300 mg group. Compared with low-dose (100 mg) users, high-dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50-0.94) and mortality (adjusted HR 0.75, 95% CI 0.59-0.94).Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality.CONCLUSIONSLess than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of ≤6 mg dl−1. • High‐dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients. WHAT THIS STUDY ADDS • Less than 50% of patients taking allopurinol reached target urate concentration. • Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality in all patients on allopurinol treatment. AIMS To characterize patients with urate measurements by urate‐lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes. METHODS A cohort study using a record‐linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined. RESULTS Six thousand and forty‐two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl−1. Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non‐ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95–1.26] and the non‐ULT group with urate >6 mg dl−1 (adjusted HR 1.07, 95% CI 0.89–1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9–86.1) per 1000 person years for the 100 mg group, 69.7 (49.6–89.8) for the 200 mg group and 47.6 (38.4–56.9) for the ≥300 mg group. Compared with low‐dose (100 mg) users, high‐dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50–0.94) and mortality (adjusted HR 0.75, 95% CI 0.59–0.94). CONCLUSIONS Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration of ≤6 mg dl −1 . • High‐dose allopurinol is associated with reduced cardiovascular events and mortality in heart failure patients. WHAT THIS STUDY ADDS • Less than 50% of patients taking allopurinol reached target urate concentration. • Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality in all patients on allopurinol treatment. AIMS To characterize patients with urate measurements by urate‐lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes. METHODS A cohort study using a record‐linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined. RESULTS Six thousand and forty‐two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl −1 . Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non‐ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95–1.26] and the non‐ULT group with urate >6 mg dl −1 (adjusted HR 1.07, 95% CI 0.89–1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9–86.1) per 1000 person years for the 100 mg group, 69.7 (49.6–89.8) for the 200 mg group and 47.6 (38.4–56.9) for the ≥300 mg group. Compared with low‐dose (100 mg) users, high‐dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50–0.94) and mortality (adjusted HR 0.75, 95% CI 0.59–0.94). CONCLUSIONS Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality. To characterize patients with urate measurements by urate-lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and mortality outcomes. A cohort study using a record-linkage database. The study included 7135 patients aged ≥60 years with urate measurements between 2000 and 2002 followed up until 2007. A Cox regression model was used. The association between urate levels, dispensed allopurinol and cardiovascular hospitalization and mortality was determined. Six thousand and forty-two patients were not taking ULT and 45.9% of those (2774 of 6042) had urate concentrations ≤6 mg dl(-1) . Among 1035 allopurinol users, 44.7% (45.6% for men and 43.3% for women) reached target urate concentration. There was no significant increased risk of cardiovascular events for allopurinol users when compared with non-ULT users [adjusted hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.95-1.26] and the non-ULT group with urate >6 mg dl(-1) (adjusted HR 1.07, 95% CI 0.89-1.28). Within the allopurinol use cohort, cardiovascular event rates were 74.0 (95% CI 61.9-86.1) per 1000 person years for the 100 mg group, 69.7 (49.6-89.8) for the 200 mg group and 47.6 (38.4-56.9) for the ≥300 mg group. Compared with low-dose (100 mg) users, high-dose (≥300 mg) users had significant reductions in the risk of cardiovascular events (adjusted HR 0.69, 95% CI 0.50-0.94) and mortality (adjusted HR 0.75, 95% CI 0.59-0.94). Less than 50% of patients taking allopurinol reached target urate concentration. Higher doses of allopurinol were associated with better control of urate and lower risks of both cardiovascular events and mortality. |
| Author | Chen, Yang Struthers, Allan D. MacDonald, Thomas M. Mackenzie, Isla S. Wei, Li |
| Author_xml | – sequence: 1 givenname: Li surname: Wei fullname: Wei, Li – sequence: 2 givenname: Isla S. surname: Mackenzie fullname: Mackenzie, Isla S. – sequence: 3 givenname: Yang surname: Chen fullname: Chen, Yang – sequence: 4 givenname: Allan D. surname: Struthers fullname: Struthers, Allan D. – sequence: 5 givenname: Thomas M. surname: MacDonald fullname: MacDonald, Thomas M. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23932736$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21395653$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUcFu1DAQtVAR3RZ-AfmCOGUZx2snOYAEq7ZUVCqH3q2J44BXjr3YSWn_vk5320JP9cWjmTfvjd47Igc-eEMIZbBk-X3aLBmXoihZKZYl5C7wuq6WN6_I4nFwQBbAQRaiFOyQHKW0AWCcSfGGHJaMN0IKviA_zoct6pGGnqJzYTtF64OjUzI0eDpFHA3VwWvjx1zb3EPfUY2xs-Eak54cRhqmUYfBvCWve3TJvNv_x-Tq9ORq_b24uDw7X3-9KLSQTVVU2AqmNS8NGG06qKQQ2LTtSoCoV7XuEDlWdaUb0Eb0RnQdgiihk9BCI_gx-bKj3U7tYLrdaU5tox0w3qqAVv0_8fa3-hWuFYca5KrJBB_3BDH8mUwa1WCTNs6hN2FKqhYVy86tqox8_6_Uo8aDfxnwYQ_IXqDrI3pt0xOON7ysuHy6WceQUjS90na89zNfaJ1ioOZg1UbN-ak5PzUHq-6DVTeZoH5G8KDxgtXPu9W_1pnbF--pb-ufc8XvADxzu-o |
| CODEN | BCPHBM |
| CitedBy_id | crossref_primary_10_1016_j_artere_2016_04_001 crossref_primary_10_1093_rheumatology_kes194 crossref_primary_10_1371_journal_pone_0099102 crossref_primary_10_1016_j_amjmed_2015_03_029 crossref_primary_10_1016_j_sciaf_2025_e02743 crossref_primary_10_1186_s12872_017_0513_6 crossref_primary_10_1007_s40266_024_01132_x crossref_primary_10_3390_jcm8122150 crossref_primary_10_12688_f1000research_9402_1 crossref_primary_10_1186_1471_2474_14_347 crossref_primary_10_1007_s10741_012_9322_2 crossref_primary_10_1177_00033197211012546 crossref_primary_10_5499_wjr_v4_i3_62 crossref_primary_10_1371_journal_pone_0260844 crossref_primary_10_1002_acr_22067 crossref_primary_10_1016_j_jaad_2013_09_005 crossref_primary_10_1093_eurheartj_ehac415 crossref_primary_10_1002_acr_24205 crossref_primary_10_1002_art_40583 crossref_primary_10_1093_rheumatology_kez576 crossref_primary_10_1016_j_mehy_2020_109791 crossref_primary_10_1016_j_amjmed_2015_01_013 crossref_primary_10_1371_journal_pone_0059121 crossref_primary_10_1016_j_rdc_2019_04_005 crossref_primary_10_1080_03007995_2023_2260304 crossref_primary_10_1161_CIRCULATIONAHA_118_033992 crossref_primary_10_1007_s10067_013_2339_7 crossref_primary_10_3389_fmed_2018_00160 crossref_primary_10_1371_journal_pone_0234909 crossref_primary_10_1590_abd1806_4841_20187547 crossref_primary_10_3389_fendo_2021_770815 crossref_primary_10_1007_s15002_013_0498_1 crossref_primary_10_1056_NEJMoa1710895 crossref_primary_10_1002_acr_24713 crossref_primary_10_1002_art_42160 crossref_primary_10_1016_j_amjmed_2015_11_003 crossref_primary_10_1111_ijcp_12428 crossref_primary_10_1093_rheumatology_kex065 crossref_primary_10_2337_db13_1396 crossref_primary_10_1016_j_repc_2014_06_002 crossref_primary_10_1097_BOR_0b013e3283513e33 crossref_primary_10_1007_s42000_022_00403_9 crossref_primary_10_1185_03007995_2013_790804 crossref_primary_10_1186_s12872_016_0379_z crossref_primary_10_1111_1440_1681_13374 crossref_primary_10_1186_1471_2261_12_108 crossref_primary_10_1186_s12916_025_04195_8 crossref_primary_10_1080_14656566_2018_1536747 crossref_primary_10_1097_MNH_0000000000000619 crossref_primary_10_1016_j_repce_2014_06_003 crossref_primary_10_1136_heartjnl_2014_306670 crossref_primary_10_1007_s00393_024_01479_x crossref_primary_10_1111_dom_13656 crossref_primary_10_1186_s12883_016_0692_2 crossref_primary_10_1111_1755_5922_12432 crossref_primary_10_1186_s13075_015_0822_z crossref_primary_10_3390_gucdd1030014 crossref_primary_10_1080_00325481_2016_1114878 crossref_primary_10_1111_eci_12039 crossref_primary_10_1007_s12325_014_0175_z crossref_primary_10_1016_j_jacc_2012_12_016 crossref_primary_10_1136_bmjopen_2023_075741 crossref_primary_10_3390_jpm12010028 crossref_primary_10_1007_s00108_015_0001_y crossref_primary_10_3389_fcvm_2023_1190069 crossref_primary_10_1080_00015385_2025_2490369 crossref_primary_10_1177_2047487317749039 crossref_primary_10_1371_journal_pone_0091961 crossref_primary_10_1371_journal_pone_0146172 |
| Cites_doi | 10.1136/ard.57.9.545 10.1136/bmj.307.6908.846 10.1136/ard.2008.091462 10.1161/01.HYP.35.3.746 10.1016/S0140-6736(10)60391-1 10.1136/ard.2006.055251 10.1002/art.10511 10.1001/jama.283.18.2404 10.1002/art.24164 10.2337/dc09-0625 10.1111/j.1742-1241.2009.02118.x 10.1159/000084073 10.1002/art.20405 10.1136/heart.87.3.229 10.1161/01.CIR.0000065637.10517.A0 10.1016/S0140-6736(09)60883-7 10.1136/bmj.315.7119.1333 10.1161/STROKEAHA.108.519793 10.1016/S0021-9150(99)00250-6 10.1001/jama.300.8.924 10.1093/rheumatology/kep069 10.1161/CIRCULATIONAHA.106.651117 10.1136/bmj.308.6921.81 10.1124/pr.58.1.6 10.1001/archinte.164.14.1546 |
| ContentType | Journal Article |
| Copyright | 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society 2015 INIST-CNRS 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. Copyright © 2011 The British Pharmacological Society |
| Copyright_xml | – notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society – notice: 2015 INIST-CNRS – notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. – notice: Copyright © 2011 The British Pharmacological Society |
| DBID | 24P AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1365-2125.2010.03887.x |
| DatabaseName | Wiley Online Library Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 607 |
| ExternalDocumentID | PMC3080649 21395653 23932736 10_1111_j_1365_2125_2010_03887_x BCP3887 |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G106/1249 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5697-7ab51cc32e0eced07655a9bb4505848cdaa3a787c90ce5fe5dda0520d60b0953 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 83 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000288249500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Thu Aug 21 18:32:28 EDT 2025 Fri Jul 11 07:08:05 EDT 2025 Mon Jul 21 06:03:59 EDT 2025 Mon Jul 21 09:17:22 EDT 2025 Tue Nov 18 22:36:06 EST 2025 Sat Nov 29 03:44:50 EST 2025 Wed Jan 22 16:32:53 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Hypouricemic agent Prognosis Enzyme Allopurinol Mortality cardiovascular event Enzyme inhibitor Cardiovascular disease Pyrazolopyrimidine derivatives urate Xanthine oxidase Oxidoreductases Circulatory system |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5697-7ab51cc32e0eced07655a9bb4505848cdaa3a787c90ce5fe5dda0520d60b0953 |
| Notes | http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms Re‐use of this article is permitted in accordance with the Terms and Conditions set out at ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2010.03887.x |
| PMID | 21395653 |
| PQID | 857130647 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3080649 proquest_miscellaneous_857130647 pubmed_primary_21395653 pascalfrancis_primary_23932736 crossref_citationtrail_10_1111_j_1365_2125_2010_03887_x crossref_primary_10_1111_j_1365_2125_2010_03887_x wiley_primary_10_1111_j_1365_2125_2010_03887_x_BCP3887 |
| PublicationCentury | 2000 |
| PublicationDate | April 2011 |
| PublicationDateYYYYMMDD | 2011-04-01 |
| PublicationDate_xml | – month: 04 year: 2011 text: April 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd Blackwell Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell – name: Blackwell Science Inc |
| References | 2009; 68 2004; 164 2009; 63 1997; 315 1993; 307 2009; 61 2006; 33 2006; 58 2008; 39 2005 1999; 147 2001; 28 2003 2008; 300 2009; 48 2006; 114 2005; 25 2002; 47 2004; 51 2003; 107 2009; 32 2006; 65 2000; 35 2002; 87 2010; 375 2000; 283 1994; 308 1998; 57 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_2_2 e_1_2_7_9_2 (e_1_2_7_15_2) 1994; 308 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 Li‐Yu J (e_1_2_7_3_2) 2001; 28 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_10_2 e_1_2_7_27_2 e_1_2_7_28_2 Dalbeth N (e_1_2_7_26_2) 2006; 33 e_1_2_7_29_2 Wei L (e_1_2_7_14_2) 2005 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_23_2 e_1_2_7_22_2 e_1_2_7_21_2 e_1_2_7_20_2 |
| References_xml | – volume: 315 start-page: 1333 year: 1997 end-page: 7 article-title: Association of upper gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs with continued exposure: cohort study publication-title: BMJ – volume: 28 start-page: 577 year: 2001 end-page: 80 article-title: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? publication-title: J Rheumatol – volume: 65 start-page: 1301 year: 2006 end-page: 11 article-title: EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) publication-title: Ann Rheum Dis – volume: 63 start-page: 1327 year: 2009 end-page: 33 article-title: Association between Allopurinol and mortality in heart failure patients: a long‐term follow‐up study publication-title: Int J Clin Pract – volume: 48 start-page: 804 year: 2009 end-page: 6 article-title: Allopurinol and mortality in hyperuricaemic patients publication-title: Rheumatology – year: 2003 – volume: 51 start-page: 321 year: 2004 end-page: 5 article-title: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy publication-title: Arthritis Rheum – volume: 307 start-page: 846 year: 1993 end-page: 8 article-title: Primary non‐compliance with prescribed medication in primary care publication-title: BMJ – volume: 35 start-page: 746 year: 2000 end-page: 51 article-title: Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics with Mild Hypertension publication-title: Hypertension – volume: 107 start-page: 1991 year: 2003 end-page: 7 article-title: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging publication-title: Circulation – volume: 33 start-page: 1646 year: 2006 end-page: 50 article-title: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout publication-title: J Rheumatol – volume: 61 start-page: 225 year: 2009 end-page: 32 article-title: Serum uric acid level as an independent risk factor for all‐cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study publication-title: Arthritis Rheum – volume: 375 start-page: 318 year: 2010 end-page: 28 article-title: Gout publication-title: Lancet – volume: 47 start-page: 356 year: 2002 end-page: 60 article-title: Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout publication-title: Arthritis Rheum – volume: 87 start-page: 229 year: 2002 end-page: 34 article-title: Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study publication-title: Heart – volume: 39 start-page: 3303 year: 2008 end-page: 7 article-title: Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double‐blind, placebo‐controlled trial publication-title: Stroke – volume: 57 start-page: 545 year: 1998 end-page: 9 article-title: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout publication-title: Ann Rheum Dis – volume: 308 start-page: 81 year: 1994 end-page: 106 article-title: Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients publication-title: BMJ – volume: 283 start-page: 2404 year: 2000 end-page: 10 article-title: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow‐up study, 1971‐1992. National Health and Nutrition Examination Survey publication-title: JAMA – volume: 164 start-page: 1546 year: 2004 end-page: 51 article-title: Uric acid level as a risk factor for cardiovascular and all‐cause mortality in middle‐aged men: a prospective cohort study publication-title: Arch Intern Med – volume: 25 start-page: 36 year: 2005 end-page: 44 article-title: Uric acid, microalbuminuria and cardiovascular events in high‐risk patients publication-title: Am J Nephrol – volume: 32 start-page: 1716 year: 2009 end-page: 20 article-title: Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients publication-title: Diabetes Care – volume: 68 start-page: 892 year: 2009 end-page: 7 article-title: randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout publication-title: Ann Rheum Dis – volume: 58 start-page: 87 year: 2006 end-page: 114 article-title: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol publication-title: Pharmacol Rev – volume: 300 start-page: 924 year: 2008 end-page: 32 article-title: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial publication-title: JAMA – volume: 114 start-page: 2508 year: 2006 end-page: 16 article-title: High‐dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid publication-title: Circulation – start-page: 323 year: 2005 end-page: 36 – volume: 147 start-page: S11 issue: 1 year: 1999 end-page: 6 article-title: Beyond lipids – the role of the endothelium in coronary artery disease publication-title: Atherosclerosis – volume: 375 start-page: 2161 year: 2010 end-page: 7 article-title: Effect of high‐dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial publication-title: Lancet – ident: e_1_2_7_5_2 doi: 10.1136/ard.57.9.545 – ident: e_1_2_7_29_2 doi: 10.1136/bmj.307.6908.846 – ident: e_1_2_7_6_2 doi: 10.1136/ard.2008.091462 – ident: e_1_2_7_30_2 – ident: e_1_2_7_12_2 doi: 10.1161/01.HYP.35.3.746 – ident: e_1_2_7_21_2 doi: 10.1016/S0140-6736(10)60391-1 – ident: e_1_2_7_24_2 doi: 10.1136/ard.2006.055251 – ident: e_1_2_7_4_2 doi: 10.1002/art.10511 – ident: e_1_2_7_9_2 doi: 10.1001/jama.283.18.2404 – ident: e_1_2_7_10_2 doi: 10.1002/art.24164 – ident: e_1_2_7_7_2 doi: 10.2337/dc09-0625 – ident: e_1_2_7_16_2 doi: 10.1111/j.1742-1241.2009.02118.x – volume: 33 start-page: 1646 year: 2006 ident: e_1_2_7_26_2 article-title: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout publication-title: J Rheumatol – ident: e_1_2_7_19_2 doi: 10.1159/000084073 – ident: e_1_2_7_2_2 doi: 10.1002/art.20405 – ident: e_1_2_7_13_2 doi: 10.1136/heart.87.3.229 – ident: e_1_2_7_8_2 doi: 10.1161/01.CIR.0000065637.10517.A0 – ident: e_1_2_7_25_2 doi: 10.1016/S0140-6736(09)60883-7 – ident: e_1_2_7_28_2 doi: 10.1136/bmj.315.7119.1333 – start-page: 323 volume-title: Pharmacoepidemiology year: 2005 ident: e_1_2_7_14_2 – ident: e_1_2_7_27_2 doi: 10.1161/STROKEAHA.108.519793 – ident: e_1_2_7_20_2 doi: 10.1016/S0021-9150(99)00250-6 – ident: e_1_2_7_22_2 doi: 10.1001/jama.300.8.924 – ident: e_1_2_7_23_2 doi: 10.1093/rheumatology/kep069 – ident: e_1_2_7_18_2 doi: 10.1161/CIRCULATIONAHA.106.651117 – volume: 308 start-page: 81 year: 1994 ident: e_1_2_7_15_2 article-title: Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients publication-title: BMJ doi: 10.1136/bmj.308.6921.81 – ident: e_1_2_7_17_2 doi: 10.1124/pr.58.1.6 – ident: e_1_2_7_11_2 doi: 10.1001/archinte.164.14.1546 – volume: 28 start-page: 577 year: 2001 ident: e_1_2_7_3_2 article-title: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? publication-title: J Rheumatol |
| SSID | ssj0013165 |
| Score | 2.3171775 |
| Snippet | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Guidelines recommend that the therapeutic goal of urate‐lowering therapy (ULT) is to achieve a urate concentration... To characterize patients with urate measurements by urate-lowering therapy (ULT) use and to study the impact of allopurinol treatment on cardiovascular and... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 600 |
| SubjectTerms | Aged Aged, 80 and over allopurinol Allopurinol - therapeutic use Biological and medical sciences Cardiovascular Diseases - etiology Cardiovascular Diseases - mortality cardiovascular event Cohort Studies Female Gout - complications Gout - drug therapy Gout - mortality Gout Suppressants - therapeutic use Hospitalization - statistics & numerical data Humans Hyperuricemia - complications Hyperuricemia - drug therapy Hyperuricemia - mortality Male Medical sciences mortality Pharmacoepidemiology Pharmacology. Drug treatments Proportional Hazards Models Risk Factors Time Factors Treatment Outcome United Kingdom urate Uric Acid - analysis |
| Title | Impact of allopurinol use on urate concentration and cardiovascular outcome |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2010.03887.x https://www.ncbi.nlm.nih.gov/pubmed/21395653 https://www.proquest.com/docview/857130647 https://pubmed.ncbi.nlm.nih.gov/PMC3080649 |
| Volume | 71 |
| WOSCitedRecordID | wos000288249500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2125 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2125 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013165 issn: 0306-5251 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYl6aFQ0nfrPhYdSk5xsdd6-ZikXRpaFlO2dG9GL5NAsJd4HZJ_nxnZ2Y1pDqH0YmTsMdZ4xvokzXxDyOe00k7CMBm7aZ7EDDBynEMz1jmgCZcpXhkWik3I-Vwtl3kxxD9hLkzPD7FZcEPPCP9rdHBt2rGThwgtGKGHCK0MHOYL4MndNM0UlnGYsmK7o5CGspIIkWHyxdNxVM-9TxoNVU9XugWtVX25i_vw6N9hlXfhbhivZs_-Z0-fk70BtdLD3sxekEe-fkn2i572-vqALrZZXO0B3afFlhD7-hX5cRJSMWlTUdzmX-ECf3NOu9bTpqYdklVQi-mT9cDhS3XtqB1FytKmW8N7-9dkMfu2OP4eD0UcYstFLmOpDU-tzaY-8da7RArOdW4MA-ilmLJO60zDX8PmifW88tw5jbE5TiQGufDekJ26qf07QkXCKqGNZ5IbJqwyNjMe-fRzOfWWqYjI289V2oHgHOtsnJd3JjqgyBIVWaIiy6DI8ioi6UZy1ZN8PEBmMrKIjSByygEmFBGhtyZSgsviPoyufdO1peIyxYmfjMjb3mK2wgDIAWJn0JeRLW1uQDbw8ZX67DSwgmeA_QXLIyKCLT24I-XRcYGt9_8q-IE86RfaMZzpI9lZX3T-E3lsL9dn7cUkeCEc5VJNyO7XX7PfP-Hsz8n8BuTFM7Y |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlLbRQkr7rpk11KDnFxV7rYR3b0JAl6bKHheYm9DIJBHuJ16X595mRnd2Y5hBKbwZ7jDWekT6NZr4h5EteGS9hmUz9RGUpA4ycKrhMjQI04YuSV5bFZhNyNivPztR8aAeEtTA9P8Q64IaeEedrdHAMSI-9PKZowRI9pGgV4DFfAVA-ZoA7sI_Dr-lsc6SQx76SiJFh98XzcVrPvW8arVXPl6YFtVV9v4v7AOnfeZV38W5csI52_utQX5DtAbfSb72hvSSPQv2K7M974uvrA7rY1HG1B3SfzjeU2Nevyck0FmPSpqJ40L_EEH9zSbs20KamHdJVUIcFlPXA4ktN7akb5crSplvBh4c3ZHH0Y3F4nA5tHFLHhZKpNJbnzhWTkAUXfCYF50ZZywB8lax03pjCwLzhVOYCrwL33mB2jheZRTa8t2SrburwnlCRsUoYG5jklglXWlfYgIz6Sk6CY2VC5O3_0m6gOMdOG5f6zlYHFKlRkRoVqaMi9Z-E5GvJZU_z8QCZvZFJrAWRVQ5QoUgIvbURDU6LJzGmDk3X6pLLHLd-MiHvepPZCAMkB5BdwFhGxrR-APnAx3fqi_PIC14A-hdMJUREY3rwQPT3wzleffhXwc_k6fHi56k-nc5OdsmzPuyOyU0fydbqqgufyBP3e3XRXu1Fl7wB5Co0dw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9wwDBbjOsZgrPu9bF3nh9GnZiQXO04et7bHSssRxg36ZhzboYWSHM1lrP_9JCe9a2gfythbIFGIFcn6bEufAL7ElbYSw2Rop3kUcsTIYY6Xoc4RTdgkE1XJfbMJOZ9nZ2d5MbQDolqYnh9iveFGnuHna3Jwt7TV2Mt9ihaG6CFFK0GP-YqAcotTT5kJbB3-nP063RwqxL6zJKFkXH-JeJzYc--7RtHq2VK3qLiq73hxHyS9m1l5G_H6kDXb_q-DfQHPB-TKvvWm9hIeufoV7BU99fX1PltsKrnafbbHig0p9vVrODn25ZisqRgd9S9pk7-5ZF3rWFOzjggrmKESynrg8WW6tsyMsmVZ063ww90bWMyOFgc_wqGRQ2hEmstQ6lLExiRTFznjbCRTIXRelhzhV8YzY7VONM4cJo-ME5UT1mrKz7FpVBIf3luY1E3t3gNLI16lunRcipKnJitNUjri1M_l1BmeBSBv_pcyA8k59dq4VLcWO6hIRYpUpEjlFan-BBCvJZc90ccDZHZHJrEWJF45xIVpAOzGRhS6LZ3F6No1XasyIWNa_MkA3vUmsxFGUI4wO8GxjIxp_QAxgo_v1Bfnnhk8Qfyf8jyA1BvTgweivh8UdPXhXwU_w5PicKZOj-cnH-Fpv-9O2U07MFldde4TPDa_Vxft1e7gk38BB-81IA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+allopurinol+use+on+urate+concentration+and+cardiovascular+outcome&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Wei%2C+Li&rft.au=Mackenzie%2C+Isla+S&rft.au=Chen%2C+Yang&rft.au=Struthers%2C+Allan+D&rft.date=2011-04-01&rft.eissn=1365-2125&rft.volume=71&rft.issue=4&rft.spage=600&rft_id=info:doi/10.1111%2Fj.1365-2125.2010.03887.x&rft_id=info%3Apmid%2F21395653&rft.externalDocID=21395653 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |